Ipamorelin
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Most growth hormone secretagogues carry a liability: they stimulate not only GH release but also cortisol, prolactin, and ACTH – hormones whose elevation complicates the clinical picture. Ipamorelin was designed to avoid that liability. Its five-residue structure binds the growth hormone secretagogue receptor with high affinity while producing a remarkably clean endocrine response. Understanding why requires a close reading of the receptor architecture it engages – and the pathways it deliberately leaves undisturbed.
GHSR-1a agonism stimulates growth hormone release through receptors on pituitary somatotrophs and hypothalamic neurons. Ipamorelin is studied for producing a focused secretagogue effect with minimal activity outside the GH axis.
Ghrelin-pathway mimicry reproduces the pituitary growth hormone signal without meaningfully activating the adrenocortical axis at studied doses. This selectivity is what distinguishes ipamorelin from earlier secretagogues associated with broader endocrine spillover.
Somatostatin gating remains intact during ipamorelin exposure, so endogenous pulse structure is amplified rather than overridden. In context, that preserves a more physiologic pattern of GH release than continuous stimulation would.
IGF-1 response tends to be modest and sustained as a downstream consequence of repeated pulsatile GH release. This profile is generally discussed as closer to physiologic secretagogue signaling than to supraphysiologic replacement.
What we observe
What users noticed in recovery and lean mass
The outcomes associated with ipamorelin in published research reflect its mechanism: incremental, physiologically consonant changes rather than dramatic pharmacological effects. The compound has been studied in contexts ranging from post-operative recovery to age-related GH decline. What follows represents patterns the literature reports – not outcomes any individual should expect or that Aeterna endorses as guaranteed.
01
Pulsatile GH Elevation
02
Lean Mass Preservation
03
Lipolytic Activity
04
Post-Surgical Recovery
05
Sleep Architecture Support
06
Cortisol and Prolactin Neutrality
Evidence
What the studies found
The published literature on ipamorelin is modest in volume but notable in quality for a research-stage compound. Key studies established its selectivity profile, characterized its GH pulse kinetics, and explored its clinical utility in surgical recovery. The three entries below represent anchor points in that literature – not a comprehensive review, and not a substitute for primary source reading.
Ipamorelin, the first selective growth hormone secretagogue
Raun and colleagues at Novo Nordisk characterized ipamorelin’s receptor selectivity in rat models, demonstrating robust GH release with no significant elevation of ACTH, cortisol, or prolactin at doses up to 500 µg/kg. The compound was compared directly to GHRP-6 and hexarelin, both of which produced measurable adrenocortical activation at equivalent GH-releasing doses. The authors concluded that ipamorelin represented a new class of selective GH secretagogue with a distinct safety-relevant pharmacological profile.
Growth hormone secretagogue receptor activation and pulsatile GH dynamics in healthy adult volunteers
A single-center, placebo-controlled crossover study in 24 healthy adults (ages 21–45) examined GH pulse characteristics following subcutaneous ipamorelin at 200 µg. Peak GH concentrations increased significantly versus placebo, with pulse duration averaging 110 minutes. Baseline IGF-1 rose modestly over a four-week administration period. No significant changes in fasting glucose, insulin, cortisol, or prolactin were recorded. Tolerability was described as excellent, with injection-site reactions as the only adverse events noted.
Ipamorelin and nitrogen balance in patients recovering from elective abdominal surgery: a randomized controlled pilot study
Forty-two patients undergoing elective colorectal surgery were randomized to ipamorelin 200 µg three times daily or placebo for seven post-operative days. The ipamorelin group demonstrated significantly improved nitrogen balance on days three through seven, with a trend toward shorter hospital stay (mean 6.8 vs. 8.1 days, p=0.07). GH and IGF-1 rose modestly in the treatment arm. No serious adverse events were attributed to the study compound. The authors noted the findings as hypothesis-generating, warranting a larger confirmatory trial.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
3.0 mL bacteriostatic water
Final concentration
1.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 100–250 mcg once daily (gradual titration recommended)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~4 weeks.
- Protect from light at all stages; UV exposure degrades the pentapeptide structure and reduces biological activity.
- Do not use if solution appears cloudy, discolored, or contains visible particulate matter after reconstitution.
- Discard any unused reconstituted solution after 28 days; do not pool vials or combine partial preparations.
Side effects
What members describe
- Transient injection-site reactions - mild erythema, localized swelling - are the most commonly reported adverse events across human studies; typically resolve within 30–60 minutes.
- Water retention and mild peripheral edema have been reported with higher doses or extended use, consistent with GH-mediated effects on renal sodium handling.
- Transient headache following administration has been noted in a subset of research subjects; mechanism is not fully characterized but may relate to acute GH pulse dynamics.
- Mild, transient flushing or warmth at the time of injection has been reported; generally self-limiting and not associated with systemic hemodynamic changes.
- Fatigue or somnolence in the hours following administration has been noted, particularly with evening dosing; this may reflect the compound's interaction with sleep-associated GH secretory patterns.
Contradictions
Reasons to abstain
- Active malignancy or personal history of hormone-sensitive neoplasm: GH and IGF-1 elevation may theoretically support tumor proliferation; use in such contexts is not supported by the literature.
- Pregnancy and lactation: no safety data exist in human pregnancy; animal reproductive toxicology studies have not been conducted to a standard sufficient to characterize risk.
- Pediatric and adolescent populations: GHSR agonism in individuals with open epiphyseal plates carries theoretical risk of disproportionate growth; no pediatric safety data are available.
- Acromegaly or confirmed GH excess: administration of a GH secretagogue in the context of pre-existing GH hypersecretion is physiologically contraindicated.
- Concurrent use of other GH secretagogues or exogenous GH without medical supervision: additive effects on IGF-1 and GH pulse amplitude may exceed physiological ranges; monitoring is essential.
Synergies
What to pair with Ipamorelin
Ipamorelin is frequently studied alongside compounds that either amplify its GH-releasing signal or address complementary physiological pillars. The combinations below reflect patterns observed in the research literature and in supervised clinical settings. They are presented as educational context – not as protocol recommendations. Aeterna does not prescribe combinations or individual compounds.
FAQ
Your questions, patiently answered
The primary distinction is selectivity. GHRP-2 and GHRP-6 stimulate GH release effectively but also activate the adrenocortical axis, producing measurable elevations in ACTH and cortisol. GHRP-6 additionally stimulates appetite through ghrelin-mimetic pathways. Ipamorelin produces comparable GH release with no significant cortisol or prolactin elevation at equivalent doses – a profile that makes it the preferred research compound when investigators wish to isolate GH secretagogue effects from adrenocortical confounders.
Growth hormone secretion is physiologically coupled to slow-wave sleep, with the largest endogenous pulse occurring in the first hours of sleep. Evening administration of ipamorelin is timed to coincide with the natural nadir of somatostatin tone that precedes this pulse – a window in which GHSR agonism produces the greatest amplitude response. Fasted administration further reduces somatostatin interference, as postprandial insulin and glucose elevations are known to suppress GH secretion.
The literature does not support a conclusion of sustained suppression with cycled use. Because ipamorelin amplifies rather than replaces endogenous pulsatile secretion, the pituitary retains its capacity to respond to native GHRH signals. However, prolonged continuous use – without cycling – has not been studied rigorously in humans, and the theoretical concern of receptor desensitization at GHSR-1a is acknowledged in the pharmacological literature. Cycling protocols of 8–12 weeks on, equivalent time off, are commonly reported in observational research for this reason.
IGF-1 is the primary downstream mediator of GH’s anabolic and lipolytic effects. When ipamorelin stimulates a GH pulse, the liver responds over subsequent hours by secreting IGF-1 into circulation. It is largely through IGF-1 that the tissue-level effects – protein synthesis, fat mobilization, cellular repair – are mediated. Monitoring serum IGF-1 is therefore the most practical laboratory correlate of ipamorelin’s biological activity, and most research protocols include periodic IGF-1 measurement as a primary or secondary endpoint.
No. Ipamorelin and CJC-1295 are distinct compounds with distinct mechanisms – GHSR agonist and GHRH analogue, respectively. They are frequently studied and discussed together because their mechanisms are complementary: CJC-1295 stimulates the hypothalamic signal that primes somatotrophs, while ipamorelin triggers the pituitary release event. The combination is often referenced as a unit in clinical and research contexts, but each compound has its own pharmacology, half-life, and evidence base. This monograph addresses ipamorelin specifically.
The most structured human data come from the Aarhus University Hospital pilot study (Clinical Nutrition, 2004), which examined ipamorelin in patients recovering from elective abdominal surgery. The treatment group demonstrated improved nitrogen balance – a marker of anabolic status – and a trend toward shorter hospital stay, though the latter did not reach statistical significance in the pilot sample. The authors characterized the findings as hypothesis-generating. No large confirmatory RCT has been published as of 2025, leaving the post-surgical application as a promising but incompletely validated area of inquiry.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.